ASTRAZEN Stock Overview
A biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
AstraZeneca Pharma India Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹7,611.85 |
| 52 Week High | ₹8,139.00 |
| 52 Week Low | ₹4,785.00 |
| Beta | 0.34 |
| 1 Month Change | 10.60% |
| 3 Month Change | 4.17% |
| 1 Year Change | 33.02% |
| 3 Year Change | 171.81% |
| 5 Year Change | 165.67% |
| Change since IPO | 1,147.84% |
Recent News & Updates
Recent updates
Investors Appear Satisfied With AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Prospects
Dec 31
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors
Sep 18We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability
Jun 03Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S
May 22We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease
Apr 04Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Nov 10AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00
Jul 06Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Jun 16Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
Aug 02Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock
Feb 25Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Feb 04Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Jan 18
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years
Dec 31We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability
Dec 13Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching
Nov 25Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay
Nov 07What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Oct 20AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Sep 24If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today
Aug 28What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?
Aug 02Shareholder Returns
| ASTRAZEN | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 5.2% | 3.4% | 1.6% |
| 1Y | 33.0% | 19.3% | 5.5% |
Return vs Industry: ASTRAZEN exceeded the Indian Pharmaceuticals industry which returned 19.3% over the past year.
Return vs Market: ASTRAZEN exceeded the Indian Market which returned 5.5% over the past year.
Price Volatility
| ASTRAZEN volatility | |
|---|---|
| ASTRAZEN Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: ASTRAZEN has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ASTRAZEN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 800 | Sanjeev Panchal | www.astrazeneca.in |
AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease, renal, and metabolism medicines under the CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL brand names; oncology medicines under the TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes and immunology diseases.
AstraZeneca Pharma India Limited Fundamentals Summary
| ASTRAZEN fundamental statistics | |
|---|---|
| Market cap | ₹189.84b |
| Earnings (TTM) | ₹819.20m |
| Revenue (TTM) | ₹14.85b |
233.1x
P/E Ratio12.9x
P/S RatioIs ASTRAZEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASTRAZEN income statement (TTM) | |
|---|---|
| Revenue | ₹14.85b |
| Cost of Revenue | ₹8.24b |
| Gross Profit | ₹6.60b |
| Other Expenses | ₹5.78b |
| Earnings | ₹819.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 11, 2025
| Earnings per share (EPS) | 32.77 |
| Gross Margin | 44.46% |
| Net Profit Margin | 5.52% |
| Debt/Equity Ratio | 0% |
How did ASTRAZEN perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield37%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 14:15 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AstraZeneca Pharma India Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kameswari V. S. Chavali | FirstCall Research |